Clinical Trials

GSK plc has announced positive results coming from its two pivotal phase III trials - the B-Well 1 and B-Well 2 phase III trials, assessing bepirovirsen, which is an investigational antisense oligonucleotide - ASO used for the treatment of...

Modern pharmaceutical manufacturing demands adaptable infrastructure capable of rapid reconfiguration to accommodate changing production requirements, making modular and portable laboratory equipment essential for contract manufacturers, clinical trial operations, and organizations pursuing capacity expansion through scalable platform technologies.

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

Takeda Pharmaceutical from Japan said on December 17, 2025, that its experimental pill for a type of skin disease, which is developed using artificial intelligence, has succeeded in two late-stage studies. Over half of the plaque psoriasis patients throughout the...

A new agreement as per which Eli Lilly and Company is going to offer almost $40 million to Indiana University - IU has come to the fore. As Eli Lilly & IU join hands to expand access to clinical...